Clinical Trials Directory

Trials / Completed

CompletedNCT06766786

Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation

Perioperative Magnesium Supplementation in Simultaneous Pancreas-Kidney Transplantation Patients

Status
Completed
Phase
—
Study type
Observational
Enrollment
40 (actual)
Sponsor
Dr Olu Bamgbade, MD, FRCPC · Academic / Other
Sex
All
Age
20 Years – 99 Years
Healthy volunteers
Not accepted

Summary

Magnesium is essential in human physiology. Simultaneous pancreas-kidney (SPK) transplant recipients frequently experience hypomagnesemia. The effects of hypomagnesaemia are harmful. This observational study assessed intraoperative magnesium supplementation's utility in patients undergoing SPK transplantation. Perioperative hemodynamics were monitored. Postoperative serum magnesium was monitored at 12 hours and 48 hours.

Detailed description

A vital component of human physiology is magnesium. It is common for recipients of simultaneous pancreas-kidney (SPK) transplants to have hypomagnesemia. The consequences of hypomagnesaemia are detrimental. This prospective observational study evaluated the effectiveness and safety of intraoperative magnesium supplementation in adult SPK transplant recipients. Arrhythmia and perioperative hemodynamics were observed. Serum magnesium levels were checked 12 and 48 hours after surgery.

Conditions

Interventions

TypeNameDescription
DRUGMagnesium Sulfate high dosePatients undergoing simultaneous pancreas-kidney (SPK) transplantation who gave their consent were given an intravenous magnesium supplement at a dose of 45-50 mg/kg over the course of an hour during the procedure.

Timeline

Start date
2008-01-02
Primary completion
2020-02-20
Completion
2020-02-20
First posted
2025-01-09
Last updated
2025-01-09

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT06766786. Inclusion in this directory is not an endorsement.